|
|
Vaccine Detail
|
Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007140
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: GM-CSF (NCIT_C2445)
- GM-CSF
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Pancreatic Cancer (NCT00389610). A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation of hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth (NCIT_C2445).
|
| Host Response |
|
|
| References |
NCIT_C2445: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2445]
NCT00389610: [https://clinicaltrials.gov/ct2/show/NCT00389610]
|
|
